{"id":888200,"date":"2025-09-22T07:28:05","date_gmt":"2025-09-22T11:28:05","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/quidelortho-announces-availability-of-quickvue-influenza-sars-test-for-professional-use\/"},"modified":"2025-09-22T07:28:05","modified_gmt":"2025-09-22T11:28:05","slug":"quidelortho-announces-availability-of-quickvue-influenza-sars-test-for-professional-use","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/quidelortho-announces-availability-of-quickvue-influenza-sars-test-for-professional-use\/","title":{"rendered":"QuidelOrtho Announces Availability of QUICKVUE\u2122 Influenza + SARS Test for Professional Use"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n
\n SAN DIEGO<\/span>
\n <\/span>, Sept. 22, 2025<\/span><\/span> \/PRNewswire\/ — Building on its leadership in point-of-care diagnostic testing,\u00a0QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a leading global provider of innovative in vitro diagnostic technologies, is expanding its QUICKVUE portfolio with the QUICKVUE Influenza + SARS Test, a CLIA-waived, 510(k)\u2013cleared rapid, easy-to-use immunoassay designed for professional use in physician office laboratories, urgent care centers, emergency departments, pharmacies and decentralized<\/span> hospital labs.<\/p>\n

\n

\n
\n \"QUICKVUE\u2122
\n <\/a>\n <\/p>\n<\/p><\/div>\n

The QUICKVUE Influenza + SARS Test is designed to deliver\u00a0rapid, simultaneous detection and differentiation of influenza A, influenza B and SARS-CoV-2 antigens<\/b>\u00a0from a single patient sample, providing results in as fast as\u00a010 minutes. <\/b>This capability can help clinicians distinguish between COVID-19 and seasonal flu infections, which present similar symptoms, enabling timely treatment decisions and improved patient outcomes.<\/p>\n

\n Key Features and Benefits:<\/b>\n <\/p>\n